EP1617890B1 - Medical device with antimicrobial layer - Google Patents
Medical device with antimicrobial layer Download PDFInfo
- Publication number
- EP1617890B1 EP1617890B1 EP04760444A EP04760444A EP1617890B1 EP 1617890 B1 EP1617890 B1 EP 1617890B1 EP 04760444 A EP04760444 A EP 04760444A EP 04760444 A EP04760444 A EP 04760444A EP 1617890 B1 EP1617890 B1 EP 1617890B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- medical device
- antimicrobial compound
- wall
- hydrophilic polymer
- cuff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000845 anti-microbial effect Effects 0.000 title abstract description 25
- 239000004599 antimicrobial Substances 0.000 claims abstract description 66
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 45
- 229910052709 silver Inorganic materials 0.000 claims abstract description 31
- 239000004332 silver Substances 0.000 claims abstract description 31
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 29
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011521 glass Substances 0.000 claims abstract description 20
- 229910052751 metal Inorganic materials 0.000 claims abstract description 19
- 239000002184 metal Substances 0.000 claims abstract description 19
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 18
- 239000011574 phosphorus Substances 0.000 claims abstract description 18
- 239000012530 fluid Substances 0.000 claims abstract description 7
- 238000000465 moulding Methods 0.000 claims description 12
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- -1 silver ions Chemical class 0.000 claims description 6
- 238000000071 blow moulding Methods 0.000 claims description 5
- 239000004800 polyvinyl chloride Substances 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 238000000748 compression moulding Methods 0.000 claims description 2
- 238000001746 injection moulding Methods 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 229920001971 elastomer Polymers 0.000 claims 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 239000000463 material Substances 0.000 description 28
- 206010035664 Pneumonia Diseases 0.000 description 17
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000000576 coating method Methods 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005660 hydrophilic surface Effects 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000005661 hydrophobic surface Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010101 extrusion blow moulding Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 244000000070 pulmonary pathogen Species 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009757 thermoplastic moulding Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/04—Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/04—Tracheal tubes
- A61M16/0434—Cuffs
- A61M16/0443—Special cuff-wall materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/046—Tracheae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M39/16—Tube connectors; Tube couplings having provision for disinfection or sterilisation
- A61M39/162—Tube connectors; Tube couplings having provision for disinfection or sterilisation with antiseptic agent incorporated within the connector
Definitions
- the present invention relates to medical devices, and more particularly, to a method of adding an antimicrobial function to a medical device.
- a process for applying a lubricious coating to a surface of a substrate is known from US 5620738 .
- VAP Ventilator Associated Pneumonia
- VAP infections Prolongation of hospitalization, ventilation, and management of VAP infections may add up to seven days in additional patient care and over $5,000 in incremental treatment costs per patient.
- the costs associated with VAP may be in excess of $1.5 billion per year. It would be desirable if costs associated with the prevention and intervention of VAP could be reduced.
- VAP may be associated with the long-term use of invasive positive pressure medical devices such as mechanical ventilators or tracheal tubes.
- Medical devices may be suction catheters, gastric feeding tubes, esophageal obturators, esophageal balloon catheters, oral and nasal airways, bronchoscopes, breathing circuits, filters, heat and moisture exchanges, or humidifiers.
- Tracheal tubes may be airway management devices such as endotracheal (ET) tubes, tracheostomy tubes, or transtracheal tubes.
- ET endotracheal
- Airway management devices such as ET tubes may be associated with VAP because they may provide a substrate upon which bacterial colonization can occur.
- Bacteria for colonization may come from inhaled aerosols and nasal, oropharyngeal, and gastric secretions. Bacteria for colonization may also result from the formation of microbial adhesions or biofilms on the surfaces of contaminated medical devices. Colonization, in turn, may lead to microaspiration of pulmonary pathogens and related lung infection.
- bacteria 18 for colonization may "flow" down an ET tube 10 from the mouth along with oral, nasal or gastric secretions. Such bacteria may flow to the area immediately before the cuff 4 and pool there, eventually becoming sessile on the outer surface of the ET tube. Microorganisms may adhere to an abiotic surface and allow complex biofilms to form. The complex biofilm may protect the microorganisms against antibiotic action.
- the accretion of antibiotic-resistant biofilms may form a reservoir of infecting microorganisms which may then migrate from the ET outer surface past the protective cuff and contaminate the trachea and lungs.
- Lung secretions containing microorganisms, blood, mucous, and cellular debris may colonize on the tip and inner lumen of the ET to form biofilms of antibiotic-resistant microorganisms.
- Such interluminal biofilms may occlude the breathing tube or migrate back into the lungs to cause further infection.
- the process of removing these biofilms and secretions with conventional suction catheters may lead to the aspiration of fragments of biofilms or infected aerosols.
- Contaminated suction catheters, feeding tubes, ventilator tubing and breathing circuits, or filters, heat and moisture exchangers, nebulizers, heated humidifiers, or other related breathing tubes or devices may be sources of microorganism contamination and thus may contribute to biofilm formation.
- One method of mitigating colonization of the tube surface by bacteria is by suctioning. Suctioning of subglottic secretions that may collect above the ET cuff may reduce the likelihood of aspiration. Routine suctioning of subglottic secretions may be associated with significant reduction of VAP.
- the Mallinckrodt Hi-Lo EvacTM tracheal tube is an example of an ET tube with an integral subglottic suctioning apparatus.
- Another method of mitigating colonization of the tube surface by bacteria is by administration of large doses of antibiotics.
- Administering large doses of antibiotics may promote the development of more disease resistant bacteriotypes and is thus undesirable.
- the present invention relates to a medical device according to claim 1, and a method for making the medical device according to claim 17. It is an object of the present invention to reduce the incidence of VAP. This object can be achieved by the features of the independent claims and further enhancements are characterized in the dependent claims.
- a medical device in a first embodiment, includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by extrusion.
- a method of making a medical device includes the actions of providing a hydrophobic polymer, extruding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
- a system for making a medical device includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall, means for producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
- a medical device in a fourth embodiment, includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by molding.
- a method of making a medical device includes the actions of providing a hydrophobic polymer, molding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and molding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
- Medical devices are devices which maybe used around or inserted into a living body.
- One such medical device may be a tube such as an ET tube.
- an ET tube is used in the following examples, the invention is not limited to ET tubes.
- the invention may apply in various embodiments to other types of medical devices, such as tubes, catheters, stents, feeding tubes, breathing circuits, intravenous tubes, breathing tubes, circuits, and related airway accessories such as connectors, adapters, filters, humidifiers, nebulizers, and prosthetics as well.
- Microbes may attach themselves to a surface before beginning colonization of the surface and the formation of biofilms.
- the colonization of a surface by microbes may require the microbes to become sessile on the surface before attaching themselves to the surface. Preventing the microbes from becoming sessile may thus inhibit the colonization of a surface by microbes.
- a biofilm may be described, in general, as a colony cooperative.
- a biofilm may furthermore be of mixed species with a high degree of specialization or order among individual members of the biofilm.
- normally inactive or quiet genes of these organisms may up-regulate, i.e . turn on, while the organisms settle on a surface, but prior to building the biofilm structure. Up-regulated organisms may become more adaptable to the colony way of life and may also become excessively virulent.
- VAP may be produced by simple planktonic (free-floating) single cell microbes that may come from leakage around the cuff, or air entering from the tube lumen. Bacteria may become sessile and also resistant to antibiotics by accretion of a protective glycocalyx coating that becomes a biofilm over time. This biofilm may then change its texture, becoming smooth, thus adding further to its defense against antibiotics. Polyvinyl chloride (PVC) may, in some cases, contribute to the formation of such biofilms.
- PVC Polyvinyl chloride
- Microbes may be more likely to become sessile on hydrophobic surfaces such as, e.g ., those of polyethylene (PE), polypropylene (PP), silicone rubber such as polydimethylsiloxane (PDMS), and PVC.
- Hydrophobic surfaces reject water.
- Hydrophilic surfaces in contrast, which are characterized by an affinity for water, may inhibit microbes from attaching themselves to the surface, and consequently inhibit the formation of biofilms as well.
- Friction between a medical device and surrounding tissue may cause irritation in the surrounding tissues such as vocal cords. Such friction may make it more difficult to insert a medical device in the first place- Such friction may also produce trauma to the surrounding tissues. It would be desirable for the surface of a medical device to have lower surface friction, so that it slid across surrounding tissues more easily.
- Biofilms may adhere to surfaces of medical devices, resulting in a buildup of dried secretions. It would be desirable for a medical device to have a slippery surface so that biofilms may be less likely to adhere to the surface of the medical device. It would be further desirable for a medical device to have a slippery surface so that biofilms that did build up might be easier to remove by suctioning techniques, so less frequent suctioning might be required.
- a medical device such as an ET tube may have a cuff.
- a cuff may form a seal around the tube to block secretions that may otherwise be aspirated. It would be desirable for such a cuff to swell in thickness upon absorbing moisture from the surrounding tissues. It would further be desirable is such a swelling resulted in an ability to seal at a lower pressure, such as a lower contact pressure between the cuff and the surrounding tissues.
- Medical devices, and in particular ET tubes are often formed of hydrophobic materials such as PVC. Microbes may be inhibited from attaching themselves to a hydrophobic surface by applying a hydrophilic layer over the hydrophobic surface.
- a medical device may be formed of, e.g . a hydrophobic material coated with a hydrophilic material to give it a hydrophilic surface.
- the hydrophilic coating may be, e.g . a polyurethane (PU), such as medical grade hydrophilic thermoplastic polyurethane.
- Hydrophilic coatings may be applied by a coating operation.
- a medical device such as an ET tube, may promote respiration. It would be desirable if the carbon dioxide (CO 2 ) content of respiration could be determined, so as to determine whether the intubation is proper. It would further be desirable if a hydrophilic surface of a medical device were injected with a chemical, such as an acid-base color dye, to indicate CO 2 concentration.
- CO 2 carbon dioxide
- Some elements may have a deleterious effect on microbes. Some of these metals may be oligodynamic, in that they have an effect in small quantities only. Some metals may kill microbes by destroying their cell walls or by interfering with the metabolic functions of the cells. These metals may thus have antimicrobial or antiseptic properties. Some examples of such metals are copper, silver, or gold. Silver or silver ions (Ag + ), for example, may be adsorbed on the bacterial cell surface as an RSAg complex-The RSAg complex may immobilize the respiratory activity of the cell and eventually kill the cell.
- the hydrophilic layer may therefore further contain a metal such as copper, silver, or gold in a metal bearing material.
- the metal may be elemental silver, powdered silver, silver ions (Ag + ), or a silver bearing material like silver oxide (AgO).
- the hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by antimicrobial properties.
- the silver bearing material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation.
- the glass may also contain trace amounts of other elements, such as calcium oxide (CaO).
- the rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water.
- the silver, or the phosphorus-based glass material, or both may be powdered.
- the hydrophilic layer may be wetted with water prior to use.
- the hydrophilic layer may also attract and absorb water available in the host during use. The absorbed water may then dissolve the silver bearing phosphorus-based glass material and release the silver into the surroundings of the medical device.
- the rate at which the silver bearing phosphorus-based glass material dissolves in water may in turn be a function of the amount of water available to dissolve it.
- the release of silver over time which is defined as the elution rate and is measured in ⁇ -grams/cm 2 /day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material.
- the silver bearing material may be made up of about 5-10 % by weight, e.g . about 7.5 % phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN.
- the elution rate should be up to about 0.01 ⁇ -grams/cm 2 /day. In another embodiment, the elution rate should be between about 0.01 and 1.0 ⁇ -grams/cm 2 /day. In a preferred embodiment, the elution rate should be, e.g . about 0.4 ⁇ -grams/cm 2 /day.
- bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer.
- bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness in substantially the same manner as silver may also provide a beneficial pharmacologic or therapeutic action.
- a hydrophilic coating may be applied to the surface of a medical device by, e.g . dipping, spraying, washing, or painting the hydrophilic coating on the surface. Since the volume of a coating is proportional to the thickness of the coating, however, a hydrophilic surface formed in one of these ways may have only a small volume within which silver is retained. Furthermore, if dipping, spraying, washing, or painting formed the hydrophilic coating, the silver may be present only on the surface of the coating.
- the hydrophilic coating may have a limited capacity to hold silver prior to delivery. Furthermore, since the silver may only reside on the surface of the hydrophilic coating, the silver may wash off prematurely, early in the use of the medical device, leaving less silver to prevent future bacteria from becoming sessile and colonizing the surface of the tube.
- hydrophilic layer were extruded or molded along with the medical device, since controlling the thickness of the extrusion or mold could then optimize the volume of the hydrophilic layer.
- a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an AM material.
- a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an AM material.
- Standard PVC material may form the wall of the medical device, along with one or more layers of an AM material.
- the AM layer may be formed on an inner or an outer surface of the medical device wall.
- the AM layer may be comprised of, e.g . polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver bearing phosphorus-based glass material.
- the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness. In a third embodiment, the AM layer may be up to about 6.35 mm in thickness. In one embodiment, substantially similar materials may form both the inner and outer surfaces of the tube.
- an inner or an outer AM layer may be simultaneously extruded with the medical device wall in a process commonly known as “co-extrusion”.
- both an inner and an outer AM layer may be extruded simultaneously with the medical device wall in a process sometimes referred to as "tri-extrusion.”
- Applying an AM layer to the surface of a medical device may reduce the incidence of VAR There may also be a production cost savings to be gained by extruding an AM layer on a medical device over a conventional coating process.
- an AM layer is also applied to the cuff portion of the medical device.
- only the outer surface of the cuff will have an AM layer since only the outer surface of the cuff is exposed to the patient.
- An AM layer may be applied to the outer surface of the cuff portion of the medical device by, e.g . co-extruding the AM layer with the wall of the cuff.
- the cuff wall may subsequently be expanded to form a thin-walled cuff device.
- the cuffwall may be expanded by, e.g . a process such as extrusion blow molding.
- a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff.
- a mold clamps the medical device around the mandrel.
- gas is admitted to the cuff area through the mandrel the cuff expands against the mold.
- the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blowmolding process.
- Medical device 100 may be a catheter, a stent, a feeding tube, an intravenous tube, an ET tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.
- Medical device 100 may have a conduit 102 for a fluid and an inflatable cuff 104 disposed at a first end 114 of conduit 102.
- the fluid may be a gas, an aerosol, a suspension, a vapor, or droplets of liquid dispersed in a gas.
- a lumen 116 may be disposed alongside conduit 102 to inflate cuff 104.
- a wall 112 of conduit 102 is made of a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound.
- a wall 412 of conduit 102 is made of a hydrophobic polymer with an outer layer 406 composed of a hydrophilic polymer and an antimicrobial compound disposed on an outer surface 408 of wall 412.
- An inner layer 404 composed of a hydrophilic polymer and an antimicrobial compound may further be disposed on an inner surface 410 of wall 412.
- Outer surface 408 may also be an outer surface of cuff 104.
- wall 412 is a hydrophobic compound containing a hydrophilic polymer and an antimicrobial compound.
- a hydrophilic polymer and an antimicrobial compound are substantially dispersed, i.e . mixed with a hydrophobic compound forming wall 412 of conduit 102.
- hydrophilic polymer and antimicrobial compound are substantially dispersed within cuff 104, with e.g . a hydrophobic compound forming cuff 104.
- a method of making a medical device 100 comprises the actions of providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, combining the hydrophilic polymer and the antimicrobial compound, forming the hydrophobic polymer into a wall 412 of a conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an outer layer 406 on a outer surface 408 of conduit 102.
- the method further includes forming the hydrophobic polymer into a cuff 104 on an end of conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound on a surface of cuff 104.
- the method further includes substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an inner layer 404 on an inner surface 410 of conduit 102 while wall 412 and outer layer 406 are being extruded.
- a resulting thickness of the hydrophilic polymer and the antimicrobial compound layer 404 is controlled by the extruder. In an alternative embodiment, extruding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound together forms a wall 412 of conduit 102.
- a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an inner layer 404 is extruded in a first predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an inner surface 410 of conduit 102.
- a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an outer layer 406 is extruded in a second predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an outer surface 408 of conduit.
- an outer layer 406 composed of a hydrophilic polymer and the antimicrobial compound in a second predetermined Formulation may be, e.g . molded on outer surface 408 of conduit 102.
- the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g . compounded together and extruded to form a wall 412 of conduit 102.
- the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g . compounded together and extruded to form a wall 114 of cuff 104.
- the hydrophilic polymer and the antimicrobial compound may be, e.g . molded on an outer surface of cuff 104.
- the hydrophilic polymer and the antimicrobial compound may be, e.g . extruded on an outer surface of cuff 104.
- cuff 104 may be, e.g . formed by extruding the hydrophobic polymer, hydrophilic polymer and antimicrobial compound into a cuff 104, and expanding cuff 104.
- a system for making a medical device 100 includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall 412, means for producing an antimicrobial compound comprising a predetermined amount ofphosphorus-based glass having a quantity of silver substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding an outer layer 406 of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface 408 of the wall 412.
- conduit 102 is formed by molding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound in a mold.
- Either the inner or the outer layers 404, 406, or both, may be molded in a mold with the wall 412.
- the molding process may be overmolding, insert molding, blow-molding, laminate blow-molding, gas assisted molding, thermoplastic molding, injection molding, or compression molding.
- a wall 412 may be formed into a tube covered by either an inner or the outer layers 404, 406 and inserted in a mold.
- the tube maybe be heated in order to promote conformance to the shape of the mold.
- a fluid such as pressurized air may be pumped into the tube so that the tube is forced or expanded against an inner surface of the mold.
- a thickness of layers 404 or 406 may be controlled by a clearance between wall 412 and an inner surface of the mold.
- a wall 412 and either an inner or outer antimicrobial compound layers 404 and 406 may be forced into a mold cavity to form the medical device.
- a wall 412 made of hydrophobic polymer is placed in a mold and the hydrophilic polymer and the antimicrobial compound layers 404 and 406 are molded around it.
- Fig. 3 is shown an extruder 300 for use with an embodiment of the invention.
- Fig. 3 may include a main extruder 302 to extrude hydrophobic polymer for the wall 412, a satellite extruder 304 for the AM material, and a satellite extruder 306 for a radio-opaque material.
- Satellite extruder 304 may feed matching gear pumps 308 to split the AM material into separate layers, one of which may be an inner layer 404 and the other an outer layer 406.
- a head 310 collects the material streams from the individual satellite extruders, combines them with the flow of material for wall 412 and extrudes them into a medical device 100.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
- The present invention relates to medical devices, and more particularly, to a method of adding an antimicrobial function to a medical device. A process for applying a lubricious coating to a surface of a substrate is known from
US 5620738 . - Ventilator-associated pneumonia may be a cause of morbidity in critically ill patients. Approximately 250,000 cases of Ventilator Associated Pneumonia (VAP) are a reported each year. The mortality associated with VAP is approximately 23,000 patients annually. (Engelmann, J. et. al.: Ventilator-Associated Pneumonia, Seminars in Infection Control, Vol. 1 No. 2 2001).
- Prolongation of hospitalization, ventilation, and management of VAP infections may add up to seven days in additional patient care and over $5,000 in incremental treatment costs per patient. The costs associated with VAP may be in excess of $1.5 billion per year. It would be desirable if costs associated with the prevention and intervention of VAP could be reduced.
- VAP may be associated with the long-term use of invasive positive pressure medical devices such as mechanical ventilators or tracheal tubes. Medical devices may be suction catheters, gastric feeding tubes, esophageal obturators, esophageal balloon catheters, oral and nasal airways, bronchoscopes, breathing circuits, filters, heat and moisture exchanges, or humidifiers. Tracheal tubes may be airway management devices such as endotracheal (ET) tubes, tracheostomy tubes, or transtracheal tubes.
- Airway management devices such as ET tubes may be associated with VAP because they may provide a substrate upon which bacterial colonization can occur. Bacteria for colonization may come from inhaled aerosols and nasal, oropharyngeal, and gastric secretions. Bacteria for colonization may also result from the formation of microbial adhesions or biofilms on the surfaces of contaminated medical devices. Colonization, in turn, may lead to microaspiration of pulmonary pathogens and related lung infection.
- As shown in
Fig. 1 ,bacteria 18 for colonization may "flow" down anET tube 10 from the mouth along with oral, nasal or gastric secretions. Such bacteria may flow to the area immediately before thecuff 4 and pool there, eventually becoming sessile on the outer surface of the ET tube. Microorganisms may adhere to an abiotic surface and allow complex biofilms to form. The complex biofilm may protect the microorganisms against antibiotic action. - The accretion of antibiotic-resistant biofilms may form a reservoir of infecting microorganisms which may then migrate from the ET outer surface past the protective cuff and contaminate the trachea and lungs. Lung secretions containing microorganisms, blood, mucous, and cellular debris may colonize on the tip and inner lumen of the ET to form biofilms of antibiotic-resistant microorganisms. Such interluminal biofilms may occlude the breathing tube or migrate back into the lungs to cause further infection.
- The process of removing these biofilms and secretions with conventional suction catheters may lead to the aspiration of fragments of biofilms or infected aerosols. Contaminated suction catheters, feeding tubes, ventilator tubing and breathing circuits, or filters, heat and moisture exchangers, nebulizers, heated humidifiers, or other related breathing tubes or devices may be sources of microorganism contamination and thus may contribute to biofilm formation.
- One method of mitigating colonization of the tube surface by bacteria is by suctioning. Suctioning of subglottic secretions that may collect above the ET cuff may reduce the likelihood of aspiration. Routine suctioning of subglottic secretions may be associated with significant reduction of VAP. The Mallinckrodt Hi-Lo Evac™ tracheal tube is an example of an ET tube with an integral subglottic suctioning apparatus.
- Suctioning, aspirating, or draining subglottic secretions, however, requires the frequent intervention of a clinician in order to be effective. It would be desirable if the incidence of VAP could be reduced without extensive reliance on suctioning. It would be desirable if the incidence of VAP could be reduced without requiring additional activities on the part of the clinician in order to be effective.
- Another method of mitigating colonization of the tube surface by bacteria is by administration of large doses of antibiotics. Administering large doses of antibiotics, however, may promote the development of more disease resistant bacteriotypes and is thus undesirable.
- The present invention relates to a medical device according to claim 1, and a method for making the medical device according to claim 17. It is an object of the present invention to reduce the incidence of VAP. This object can be achieved by the features of the independent claims and further enhancements are characterized in the dependent claims. In a first embodiment, a medical device includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by extrusion.
- In a second embodiment, a method of making a medical device includes the actions of providing a hydrophobic polymer, extruding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
- A system for making a medical device includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall, means for producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
- In a fourth embodiment, a medical device includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by molding.
- In a fifth embodiment, a method of making a medical device includes the actions of providing a hydrophobic polymer, molding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and molding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
-
-
Fig. 1 shows a medical device in situ in a trachea; -
Fig. 2 shows a plan view of a medical device according to an embodiment of the invention; -
Fig. 3 shows a schematic of an extruder for use with an embodiment of the invention; and -
Fig. 4 shows a section of a medical device according to the embodiment ofFig. 2 . - Medical devices are devices which maybe used around or inserted into a living body. One such medical device may be a tube such as an ET tube. Although an ET tube is used in the following examples, the invention is not limited to ET tubes. The invention may apply in various embodiments to other types of medical devices, such as tubes, catheters, stents, feeding tubes, breathing circuits, intravenous tubes, breathing tubes, circuits, and related airway accessories such as connectors, adapters, filters, humidifiers, nebulizers, and prosthetics as well.
- Microbes may attach themselves to a surface before beginning colonization of the surface and the formation of biofilms. The colonization of a surface by microbes may require the microbes to become sessile on the surface before attaching themselves to the surface. Preventing the microbes from becoming sessile may thus inhibit the colonization of a surface by microbes.
- A biofilm may be described, in general, as a colony cooperative. A biofilm may furthermore be of mixed species with a high degree of specialization or order among individual members of the biofilm. Additionally, normally inactive or quiet genes of these organisms may up-regulate, i.e. turn on, while the organisms settle on a surface, but prior to building the biofilm structure. Up-regulated organisms may become more adaptable to the colony way of life and may also become excessively virulent.
- Particles of biofilm may fall into the lungs during treatment. These particles may produce VAP. VAP may also be produced by simple planktonic (free-floating) single cell microbes that may come from leakage around the cuff, or air entering from the tube lumen. Bacteria may become sessile and also resistant to antibiotics by accretion of a protective glycocalyx coating that becomes a biofilm over time. This biofilm may then change its texture, becoming smooth, thus adding further to its defense against antibiotics. Polyvinyl chloride (PVC) may, in some cases, contribute to the formation of such biofilms.
- Microbes may be more likely to become sessile on hydrophobic surfaces such as, e.g., those of polyethylene (PE), polypropylene (PP), silicone rubber such as polydimethylsiloxane (PDMS), and PVC. Hydrophobic surfaces reject water. Hydrophilic surfaces, in contrast, which are characterized by an affinity for water, may inhibit microbes from attaching themselves to the surface, and consequently inhibit the formation of biofilms as well.
- Friction between a medical device and surrounding tissue may cause irritation in the surrounding tissues such as vocal cords. Such friction may make it more difficult to insert a medical device in the first place- Such friction may also produce trauma to the surrounding tissues. It would be desirable for the surface of a medical device to have lower surface friction, so that it slid across surrounding tissues more easily.
- Biofilms may adhere to surfaces of medical devices, resulting in a buildup of dried secretions. It would be desirable for a medical device to have a slippery surface so that biofilms may be less likely to adhere to the surface of the medical device. It would be further desirable for a medical device to have a slippery surface so that biofilms that did build up might be easier to remove by suctioning techniques, so less frequent suctioning might be required.
- A medical device such as an ET tube may have a cuff. Such a cuff may form a seal around the tube to block secretions that may otherwise be aspirated. It would be desirable for such a cuff to swell in thickness upon absorbing moisture from the surrounding tissues. It would further be desirable is such a swelling resulted in an ability to seal at a lower pressure, such as a lower contact pressure between the cuff and the surrounding tissues.
- Successive concentrations and rarefactions of moisture may occur across a medical device during intubation. It would be desirable if a surface of a medical device could transport moisture across such concentration gradients by, for example, osmosis. It would further be desirable if a hydrophilic layer on an inner diameter of a tracheal tube could condense and absorb moisture from exhaled gases in a cooler region of the tube and re-evaporate the warmed moisture to drier or cooler inhalation gases.
- Medical devices, and in particular ET tubes are often formed of hydrophobic materials such as PVC. Microbes may be inhibited from attaching themselves to a hydrophobic surface by applying a hydrophilic layer over the hydrophobic surface. A medical device may be formed of, e.g. a hydrophobic material coated with a hydrophilic material to give it a hydrophilic surface. The hydrophilic coating may be, e.g. a polyurethane (PU), such as medical grade hydrophilic thermoplastic polyurethane. Hydrophilic coatings may be applied by a coating operation.
- A medical device, such as an ET tube, may promote respiration. It would be desirable if the carbon dioxide (CO2) content of respiration could be determined, so as to determine whether the intubation is proper. It would further be desirable if a hydrophilic surface of a medical device were injected with a chemical, such as an acid-base color dye, to indicate CO2 concentration.
- Destroying the microbes before they have a chance to become sessile and colonize the surface of the medical device could mitigate the conditions promoting colonization. It would further be desirable for the incidence of VAP to be reduced without extensive reliance on large doses of antibiotics.
- Some elements, such as some metals, may have a deleterious effect on microbes. Some of these metals may be oligodynamic, in that they have an effect in small quantities only. Some metals may kill microbes by destroying their cell walls or by interfering with the metabolic functions of the cells. These metals may thus have antimicrobial or antiseptic properties. Some examples of such metals are copper, silver, or gold. Silver or silver ions (Ag+), for example, may be adsorbed on the bacterial cell surface as an RSAg complex-The RSAg complex may immobilize the respiratory activity of the cell and eventually kill the cell.
- The hydrophilic layer may therefore further contain a metal such as copper, silver, or gold in a metal bearing material. In several exemplary embodiments, the metal may be elemental silver, powdered silver, silver ions (Ag+), or a silver bearing material like silver oxide (AgO). The hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by antimicrobial properties.
- It may be desirable for the silver to be released over time, while the medical device is in use. In one embodiment, therefore, the silver bearing material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation. The glass may also contain trace amounts of other elements, such as calcium oxide (CaO). The rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water. The silver, or the phosphorus-based glass material, or both may be powdered.
- The hydrophilic layer may be wetted with water prior to use. The hydrophilic layer may also attract and absorb water available in the host during use. The absorbed water may then dissolve the silver bearing phosphorus-based glass material and release the silver into the surroundings of the medical device. The rate at which the silver bearing phosphorus-based glass material dissolves in water may in turn be a function of the amount of water available to dissolve it.
- The release of silver over time, which is defined as the elution rate and is measured in µ-grams/cm2/day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material. In one embodiment, the silver bearing material may be made up of about 5-10 % by weight, e.g. about 7.5 % phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN.
- In one embodiment, the elution rate should be up to about 0.01 µ-grams/cm2/day. In another embodiment, the elution rate should be between about 0.01 and 1.0 µ-grams/cm2/day. In a preferred embodiment, the elution rate should be, e.g. about 0.4 µ-grams/cm2/day.
- In other embodiments, bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer. Such bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness in substantially the same manner as silver may also provide a beneficial pharmacologic or therapeutic action.
- A hydrophilic coating may be applied to the surface of a medical device by, e.g. dipping, spraying, washing, or painting the hydrophilic coating on the surface. Since the volume of a coating is proportional to the thickness of the coating, however, a hydrophilic surface formed in one of these ways may have only a small volume within which silver is retained. Furthermore, if dipping, spraying, washing, or painting formed the hydrophilic coating, the silver may be present only on the surface of the coating.
- Since the volume of a coating is necessarily small, the hydrophilic coating may have a limited capacity to hold silver prior to delivery. Furthermore, since the silver may only reside on the surface of the hydrophilic coating, the silver may wash off prematurely, early in the use of the medical device, leaving less silver to prevent future bacteria from becoming sessile and colonizing the surface of the tube.
- It would be desirable if a hydrophilic layer were extruded or molded along with the medical device, since controlling the thickness of the extrusion or mold could then optimize the volume of the hydrophilic layer.
- In one embodiment, a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an AM material. In another embodiment, a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an AM material. Standard PVC material may form the wall of the medical device, along with one or more layers of an AM material. The AM layer may be formed on an inner or an outer surface of the medical device wall. The AM layer may be comprised of, e.g. polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver bearing phosphorus-based glass material.
- In one embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness. In a third embodiment, the AM layer may be up to about 6.35 mm in thickness. In one embodiment, substantially similar materials may form both the inner and outer surfaces of the tube.
- In one embodiment, an inner or an outer AM layer may be simultaneously extruded with the medical device wall in a process commonly known as "co-extrusion". In another embodiment, both an inner and an outer AM layer may be extruded simultaneously with the medical device wall in a process sometimes referred to as "tri-extrusion."
- Applying an AM layer to the surface of a medical device may reduce the incidence of VAR There may also be a production cost savings to be gained by extruding an AM layer on a medical device over a conventional coating process.
- In one embodiment, an AM layer is also applied to the cuff portion of the medical device. In a preferred embodiment only the outer surface of the cuff will have an AM layer since only the outer surface of the cuff is exposed to the patient. An AM layer may be applied to the outer surface of the cuff portion of the medical device by, e.g. co-extruding the AM layer with the wall of the cuff.
- The cuff wall may subsequently be expanded to form a thin-walled cuff device. The cuffwall may be expanded by, e.g. a process such as extrusion blow molding. In this process, a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff. After a length of medical device, or parison, has been extruded, a mold clamps the medical device around the mandrel. As gas is admitted to the cuff area through the mandrel the cuff expands against the mold. In the alternative, the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blowmolding process.
- In
Fig. 2 is shown amedical device 100 according to a first embodiment of the invention.Medical device 100 may be a catheter, a stent, a feeding tube, an intravenous tube, an ET tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments. -
Medical device 100 may have aconduit 102 for a fluid and aninflatable cuff 104 disposed at afirst end 114 ofconduit 102. The fluid may be a gas, an aerosol, a suspension, a vapor, or droplets of liquid dispersed in a gas. Alumen 116 may be disposed alongsideconduit 102 to inflatecuff 104. In one embodiment, awall 112 ofconduit 102 is made of a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound. - As shown in section 4-4 shown in
Fig. 4 , awall 412 ofconduit 102 is made of a hydrophobic polymer with anouter layer 406 composed of a hydrophilic polymer and an antimicrobial compound disposed on anouter surface 408 ofwall 412. Aninner layer 404 composed of a hydrophilic polymer and an antimicrobial compound may further be disposed on an inner surface 410 ofwall 412.Outer surface 408 may also be an outer surface ofcuff 104. - In one embodiment,
wall 412 is a hydrophobic compound containing a hydrophilic polymer and an antimicrobial compound. In one embodiment, a hydrophilic polymer and an antimicrobial compound are substantially dispersed, i.e. mixed with a hydrophobiccompound forming wall 412 ofconduit 102. In another embodiment, hydrophilic polymer and antimicrobial compound are substantially dispersed withincuff 104, with e.g. a hydrophobiccompound forming cuff 104. - In a second embodiment, a method of making a
medical device 100 comprises the actions of providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, combining the hydrophilic polymer and the antimicrobial compound, forming the hydrophobic polymer into awall 412 of aconduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as anouter layer 406 on aouter surface 408 ofconduit 102. - In another embodiment, the method further includes forming the hydrophobic polymer into a
cuff 104 on an end ofconduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound on a surface ofcuff 104. - in another embodiment, the method further includes substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an
inner layer 404 on an inner surface 410 ofconduit 102 whilewall 412 andouter layer 406 are being extruded. - In one embodiment, a resulting thickness of the hydrophilic polymer and the
antimicrobial compound layer 404 is controlled by the extruder. In an alternative embodiment, extruding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound together forms awall 412 ofconduit 102. - In one embodiment, a
wall 412 ofconduit 102 may be extruded from a hydrophobic compound while aninner layer 404 is extruded in a first predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an inner surface 410 ofconduit 102. In another embodiment, awall 412 ofconduit 102 may be extruded from a hydrophobic compound while anouter layer 406 is extruded in a second predetermined formulation of a hydrophilic polymer and an antimicrobial compound on anouter surface 408 of conduit. In an alternative embodiment, anouter layer 406 composed of a hydrophilic polymer and the antimicrobial compound in a second predetermined Formulation may be, e.g. molded onouter surface 408 ofconduit 102. In an alternative embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g. compounded together and extruded to form awall 412 ofconduit 102. - In one embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g. compounded together and extruded to form a
wall 114 ofcuff 104. In an alternative embodiment, the hydrophilic polymer and the antimicrobial compound may be, e.g. molded on an outer surface ofcuff 104. In an alternative embodiment, the hydrophilic polymer and the antimicrobial compound may be, e.g. extruded on an outer surface ofcuff 104. In an alternative embodiment,cuff 104 may be, e.g. formed by extruding the hydrophobic polymer, hydrophilic polymer and antimicrobial compound into acuff 104, and expandingcuff 104. - A system for making a
medical device 100 includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form awall 412, means for producing an antimicrobial compound comprising a predetermined amount ofphosphorus-based glass having a quantity of silver substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding anouter layer 406 of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over anouter surface 408 of thewall 412. - In one embodiment,
conduit 102 is formed by molding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound in a mold. Either the inner or theouter layers wall 412. The molding process may be overmolding, insert molding, blow-molding, laminate blow-molding, gas assisted molding, thermoplastic molding, injection molding, or compression molding. - A
wall 412 may be formed into a tube covered by either an inner or theouter layers layers wall 412 and an inner surface of the mold. - In one embodiment, a
wall 412 and either an inner or outer antimicrobial compound layers 404 and 406 may be forced into a mold cavity to form the medical device. In another embodiment, awall 412 made of hydrophobic polymer is placed in a mold and the hydrophilic polymer and the antimicrobial compound layers 404 and 406 are molded around it. - In
Fig. 3 is shown anextruder 300 for use with an embodiment of the invention.Fig. 3 may include amain extruder 302 to extrude hydrophobic polymer for thewall 412, asatellite extruder 304 for the AM material, and asatellite extruder 306 for a radio-opaque material.Satellite extruder 304 may feed matching gear pumps 308 to split the AM material into separate layers, one of which may be aninner layer 404 and the other anouter layer 406. Ahead 310 collects the material streams from the individual satellite extruders, combines them with the flow of material forwall 412 and extrudes them into amedical device 100. - While the invention has been described in detail above, the invention is not intended to be limited to the specific embodiments as described. It is evident that those skilled in the art may now make numerous uses and modifications of and departures from the specific embodiments described herein without departing from the claimed subject-matter.
Claims (19)
- A medical device comprising:a conduit (102) for a fluid;said conduit (102) comprising a wall (112) having an outer surface (408), said wall (112) comprising a hydrophobic polymer; andan outer layer (406) disposed on said outer surface (408), said outer layer (406) comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein;characterized in that said antimicrobial compound comprises a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein; andsaid wall (112) and said outer layer (406) are formed by extrusion or molding.
- The medical device according to claim 1, wherein said molding is overmolding, insert molding, blow-molding, laminate blow-molding, injection molding, or compression molding.
- The medical device according to claim 1 or 2, wherein said metal is copper, gold, powdered silver, substantially elemental silver, silver ions, silver oxide, or any combination thereof.
- The medical device according to claim 1, 2 or 3, wherein said wall (112) further comprises an inner surface (410);
an inner layer (404) disposed on said inner surface (410), said inner layer (404) comprising a second quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein; and
wherein said inner layer (404) is formed by extrusion. - The medical device according to claim 4, wherein a thickness of said inner layer (404) is within a range of about 0.002 mm - 2.5 mm.
- The medical device according to any of the preceding claims, wherein a thickness of said outer layer (406) is within a range of about 0.002 mm - 2.5 mm.
- The medical device according to any of the preceding claims, wherein a third quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein is substantially dispersed within said wall (112).
- The medical device according to any of the preceding claims, comprising further a cuff (104) having a cuff outer surface disposed around said medical device, a cuff outer layer disposed on said cuff outer surface, said cuff outer layer comprising a fourth quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein; and
wherein said cuff outer layer is formed by extrusion. - The medical device according to any of the preceding claims, wherein said hydrophilic polymer comprises polyurethane or medical grade hydrophilic thermoplastic polyurethane.
- The medical device according to any of the preceding claims, wherein said metal is releasable from said antimicrobial compound.
- The medical device according to claim 10, wherein said metal is released at an elution rate of up to about 0.01 µ-grams/cm2/day, at an elution rate of between about 0.01 and about 1.0 µ-grams/cm2/day, or at an elution rate of about 0.4 µ-grams/cm2/day.
- The medical device according to any of the preceding claims, wherein said predetermined amount of phosphorus-based glass comprises about 0.1 - 50 % of a weight of said antimicrobial compound.
- The medical device according to any of the preceding claims, wherein said hydrophobic polymer comprises PVC, PE, PU, PDMS, polyester, silicone, or rubber.
- The medical device according to any of the preceding claims, wherein said medical device comprises an endotracheal tube.
- The medical device according to any of the preceding claims, wherein said medical device is a catheter, a stent, a feeding tube, a breathing circuit, an intravenous tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic.
- The medical device according to any of the preceding claims, wherein said antimicrobial compound comprises further an agent in form of an indicator of a carbon dioxide concentration, a bronchodilator, an anti-inflammatory agent, or a local anesthetic.
- A method of making the medical device of any one of the preceding claims, comprising the steps of:providing the hydrophobic polymer;extruding said hydrophobic polymer to form the wall (112) of the conduit (102);producing the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein;mixing said antimicrobial compound and a hydrophilic polymer; andextruding a layer (406) of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein over an outer surface (408) of said wall (112).
- The method of making the medical device according to claim 17, further comprising the step of extruding a layer (404) of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein over an inner surface (410) of said wall (112).
- The method of making the medical device according to claim 17 or 18, further comprising the step of forming a cuff (104) on an end of said conduit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/425,030 US20040220534A1 (en) | 2003-04-29 | 2003-04-29 | Medical device with antimicrobial layer |
PCT/US2004/013196 WO2004096330A2 (en) | 2003-04-29 | 2004-04-29 | Medical device with antimicrobial layer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1617890A2 EP1617890A2 (en) | 2006-01-25 |
EP1617890B1 true EP1617890B1 (en) | 2010-06-30 |
Family
ID=33309638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04760444A Expired - Lifetime EP1617890B1 (en) | 2003-04-29 | 2004-04-29 | Medical device with antimicrobial layer |
Country Status (8)
Country | Link |
---|---|
US (4) | US20040220534A1 (en) |
EP (1) | EP1617890B1 (en) |
JP (1) | JP2006525089A (en) |
AT (1) | ATE472343T1 (en) |
AU (1) | AU2004234001B2 (en) |
CA (1) | CA2523857A1 (en) |
DE (1) | DE602004027899D1 (en) |
WO (1) | WO2004096330A2 (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2626830A1 (en) * | 1998-02-24 | 1999-08-26 | Boston Scientific Limited | High flow rate dialysis catheters and related methods |
US20050191355A1 (en) * | 1999-05-27 | 2005-09-01 | Foss Manufacturing Co., Inc. | Anti-microbial and antifungal fluid conduits and methods of manufacture thereof |
US20090165784A1 (en) * | 2007-12-28 | 2009-07-02 | Tyco Healthcare Group Lp | Lubricious intubation device |
US20040220534A1 (en) * | 2003-04-29 | 2004-11-04 | Martens Paul W. | Medical device with antimicrobial layer |
US20040254545A1 (en) * | 2003-06-16 | 2004-12-16 | Rider Dean Loller | Method and apparatus for extending feeding tube longevity |
DE102004025671A1 (en) * | 2004-05-26 | 2005-12-22 | Map Medizin-Technologie Gmbh | Arrangement for administering a respirable gas, in particular CPAP device arrangement |
ZA200700374B (en) * | 2004-06-18 | 2008-08-27 | Boc Group Inc | Antimicrobial lining for gas cylinders and coupling components |
US9457163B2 (en) | 2004-09-03 | 2016-10-04 | Virginia Commonwealth University | Prevention of ventilator associated pneumonia (VAP) |
WO2006029070A2 (en) * | 2004-09-03 | 2006-03-16 | Virginia Commonwealth University | Prevention of ventilator associated pneumonia (vap) |
WO2006089961A1 (en) * | 2005-02-28 | 2006-08-31 | Tracoe Medical Gmbh | Inhaled air supplying device |
US20070135751A1 (en) * | 2005-12-09 | 2007-06-14 | Dicarlo Paul D | Medical devices |
US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
US8434487B2 (en) * | 2006-06-22 | 2013-05-07 | Covidien Lp | Endotracheal cuff and technique for using the same |
US8196584B2 (en) * | 2006-06-22 | 2012-06-12 | Nellcor Puritan Bennett Llc | Endotracheal cuff and technique for using the same |
US20080236593A1 (en) * | 2006-06-22 | 2008-10-02 | Nellcor Puritan Bennett Llc | Endotracheal cuff and technique for using the same |
US20080051759A1 (en) * | 2006-08-24 | 2008-02-28 | Boston Scientific Scimed, Inc. | Polycarbonate polyurethane venous access devices |
US8561614B2 (en) * | 2006-09-28 | 2013-10-22 | Covidien Lp | Multi-layer cuffs for medical devices |
US20080078406A1 (en) * | 2006-09-29 | 2008-04-03 | Jessica Clayton | Endotracheal tube and technique for using the same |
US10188826B2 (en) * | 2006-09-29 | 2019-01-29 | Covidien Lp | Catheters including antimicrobial sleeve and methods of making catheters |
PL1935355T3 (en) * | 2006-12-11 | 2016-03-31 | Nutricia Nv | Tube for enteral nutrition |
US20090014009A1 (en) * | 2007-07-13 | 2009-01-15 | Kimberly-Clark Worldwide, Inc. | Toroidal endotracheal cuffs for ventilator associated pneumonia reduction |
US8607795B2 (en) | 2007-09-20 | 2013-12-17 | Kimberly-Clark Worldwide, Inc. | Balloon cuff tracheostomy tube |
US8313687B2 (en) | 2007-09-20 | 2012-11-20 | Kimberly-Clark Worldwide, Inc. | Method of making an improved balloon cuff tracheostomy tube |
WO2009049266A2 (en) | 2007-10-12 | 2009-04-16 | Conmed Corporation | Apparatus and methods for the measurement of cardiac output |
WO2009052506A1 (en) * | 2007-10-19 | 2009-04-23 | Navilyst Medical, Inc. | Recirculation minimizing catheter |
US8186351B2 (en) | 2007-12-31 | 2012-05-29 | Nellcor Puritan Bennett Llc | Reactive medical devices |
US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
US20100256546A1 (en) * | 2009-04-03 | 2010-10-07 | Davis Scott A | Polycarbonate Polyurethane Venous Access Devices Having Enhanced Strength |
US8590534B2 (en) | 2009-06-22 | 2013-11-26 | Covidien Lp | Cuff for use with medical tubing and method and apparatus for making the same |
US8821455B2 (en) * | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US8715705B2 (en) * | 2009-07-29 | 2014-05-06 | Covidien Lp | Multilayer medical devices having an encapsulated edge and methods thereof |
US8328760B2 (en) * | 2010-01-11 | 2012-12-11 | Angiodynamics, Inc. | Occlusion resistant catheter |
ES2584323T3 (en) | 2010-01-28 | 2016-09-27 | Art Healthcare Ltd. | Reflux detection and / or blocking device |
WO2011116303A1 (en) | 2010-03-19 | 2011-09-22 | Micropen Technologies Corporation | Thermocouple device |
JP5970448B2 (en) * | 2010-03-22 | 2016-08-17 | アート ヘルスケア リミテッド | Endotracheal tube having one or more blocking elements, blocking elements, and methods of using blocking elements |
WO2011117853A1 (en) * | 2010-03-22 | 2011-09-29 | Art Healthcare Ltd. | Naso/orogastric tube having one or more backflow blocking elements, backflow blocking elements, and a method of using backflow blocking elements |
US9878143B2 (en) * | 2010-09-30 | 2018-01-30 | Covidien Lp | Antimicrobial luer adapter |
US9050435B2 (en) | 2011-03-22 | 2015-06-09 | Angiodynamics, Inc. | High flow catheters |
US9999746B2 (en) | 2011-03-22 | 2018-06-19 | Angiodynamics, Inc. | High flow catheters |
US10166381B2 (en) | 2011-05-23 | 2019-01-01 | Excelsior Medical Corporation | Antiseptic cap |
WO2013009998A2 (en) | 2011-07-12 | 2013-01-17 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into trans-dermal catheter |
US9242058B2 (en) | 2011-07-29 | 2016-01-26 | Covidien Lp | Tracheal tube positioning devices and methods |
CN103877624B (en) | 2012-12-21 | 2016-05-25 | 上海微创医疗器械(集团)有限公司 | A kind of degradable polyester support and preparation method thereof |
EP3137122B1 (en) | 2014-05-02 | 2019-09-04 | Excelsior Medical Corporation | Strip package for antiseptic cap |
GB201416891D0 (en) * | 2014-09-25 | 2014-11-12 | Smiths Medical Int Ltd | Tracheal Tubes And Seals |
US20160101253A1 (en) * | 2014-10-08 | 2016-04-14 | Husam Ibrahim ALAHMADI | Protective endotracheal tube |
CA2980020C (en) | 2015-03-30 | 2023-08-01 | Giridhar Thiagarajan | Application of antimicrobial agents to medical devices |
US20180104157A1 (en) * | 2015-04-17 | 2018-04-19 | Evolve Biosystems, Inc. | Delivering non-pathogenic, intestinally beneficial bacteria to a patient having a feeding tube |
JP6822978B2 (en) | 2015-05-08 | 2021-01-27 | アイシーユー・メディカル・インコーポレーテッド | Medical connector configured to accept the emitter of a therapeutic agent |
US10064273B2 (en) | 2015-10-20 | 2018-08-28 | MR Label Company | Antimicrobial copper sheet overlays and related methods for making and using |
KR101753299B1 (en) * | 2016-01-26 | 2017-07-03 | 연세대학교 산학협력단 | Endotracheal tube and Endotracheal tube assembly |
CN107929902A (en) * | 2016-03-21 | 2018-04-20 | 周中南 | Trachea cannula tube core and preparation method thereof |
LT3484535T (en) | 2016-07-14 | 2022-02-10 | Hollister Incorporated | Hygienic medical devices having hydrophilic coating and methods of forming the same |
CA3040277A1 (en) | 2016-10-14 | 2018-04-19 | Icu Medical, Inc. | Sanitizing caps for medical connectors |
WO2018204206A2 (en) | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
CN107899089B (en) * | 2018-01-22 | 2021-03-26 | 上海士宇生物技术有限公司 | T-shaped trachea cannula containing mitomycin and having scar preventing function and preparation method thereof |
CN215915829U (en) | 2018-07-02 | 2022-03-01 | C·R·巴德股份有限公司 | Antimicrobial catheter assembly |
US11524098B2 (en) * | 2018-09-14 | 2022-12-13 | Avent, Inc. | Systems and methods for biofilm inoculation |
US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
AU2019384564B2 (en) | 2018-11-21 | 2023-11-23 | Icu Medical, Inc. | Antimicrobial device comprising a cap with ring and insert |
JP2020092911A (en) * | 2018-12-13 | 2020-06-18 | 大塚テクノ株式会社 | Urethral catheter |
USD930831S1 (en) | 2020-03-05 | 2021-09-14 | Jim Benton | Microbial barrier tubing clamp |
CA3204371A1 (en) | 2020-12-07 | 2022-06-16 | Icu Medical, Inc. | Peritoneal dialysis caps, systems and methods |
Family Cites Families (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US691104A (en) * | 1901-03-14 | 1902-01-14 | Thomas E Woodley | Machine for finishing heels and bottoms. |
US909002A (en) * | 1908-06-03 | 1909-01-05 | Napoleon Lambert | Respirator. |
US1796124A (en) * | 1927-11-30 | 1931-03-10 | Bristol Company | Temperature controller |
US3173418A (en) * | 1961-01-10 | 1965-03-16 | Ostap E Baran | Double-wall endotracheal cuff |
FR1453843A (en) * | 1965-03-18 | 1966-07-22 | Pechiney Saint Gobain | New compounds with parasiticidal action |
FR1472949A (en) * | 1965-06-29 | 1967-03-17 | Pechiney Saint Gobain | New parasiticidal ketoacetylenic products |
FR2048177A5 (en) * | 1969-06-03 | 1971-03-19 | Pechiney Saint Gobain | |
US3734100A (en) * | 1973-05-07 | 1973-05-22 | Medical Products Corp | Catheter tubes |
US4343788A (en) * | 1979-06-29 | 1982-08-10 | The Procter & Gamble Company | Antimicrobial polymer compositions |
US4328056A (en) * | 1980-07-09 | 1982-05-04 | Sherwood Medical Industries Inc. | Method of making a cuffed tube |
US4379863A (en) * | 1981-01-13 | 1983-04-12 | C. R. Bard, Inc. | Copolymer composition and delivery system for providing a protective barrier film for the skin |
US4539234A (en) * | 1981-05-27 | 1985-09-03 | Unitika Ltd. | Urethral catheter capable of preventing urinary tract infection and process for producing the same |
US4515593A (en) * | 1981-12-31 | 1985-05-07 | C. R. Bard, Inc. | Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same |
US4417892A (en) * | 1981-12-31 | 1983-11-29 | C. R. Bard, Inc. | Urine drainage bag outlet tube and method for eliminating or reducing migration of bacteria |
SE430695B (en) * | 1982-04-22 | 1983-12-05 | Astra Meditec Ab | PROCEDURE FOR THE PREPARATION OF A HYDROPHILIC COATING AND ACCORDING TO THE PROCEDURE OF MEDICAL ARTICLES |
US4603152A (en) * | 1982-11-05 | 1986-07-29 | Baxter Travenol Laboratories, Inc. | Antimicrobial compositions |
JPS59133235A (en) * | 1983-01-21 | 1984-07-31 | Kanebo Ltd | Zeolite particle-containing polymer and its production |
US4512765A (en) * | 1983-06-09 | 1985-04-23 | Rudolph Muto | Selective tracheal bronchial catheter |
US4686124A (en) * | 1983-12-12 | 1987-08-11 | Sumitomo Bakelite Company Ltd. | Thermoplastic resin-silicone rubber composite shaped article |
US4563485A (en) * | 1984-04-30 | 1986-01-07 | The Trustees Of Columbia University In The City Of New York | Injection-resistant materials and method of making same through use of nalidixic acid derivatives |
US4581028A (en) * | 1984-04-30 | 1986-04-08 | The Trustees Of Columbia University In The City Of New York | Infection-resistant materials and method of making same through use of sulfonamides |
US4584192A (en) * | 1984-06-04 | 1986-04-22 | Minnesota Mining & Manufacturing Company | Film-forming composition containing an antimicrobial agent and methods of use |
US4723950A (en) * | 1984-12-12 | 1988-02-09 | C. R. Bard, Inc. | Urine drainage bag outlet with barrier against microbial infection |
US4642267A (en) * | 1985-05-06 | 1987-02-10 | Hydromer, Inc. | Hydrophilic polymer blend |
SE8504501D0 (en) * | 1985-09-30 | 1985-09-30 | Astra Meditec Ab | METHOD OF FORMING AN IMPROVED HYDROPHILIC COATING ON A POLYMER SURFACE |
US4917686A (en) * | 1985-12-16 | 1990-04-17 | Colorado Biomedical, Inc. | Antimicrobial device and method |
GB8616294D0 (en) * | 1986-07-03 | 1986-08-13 | Johnson Matthey Plc | Antimicrobial compositions |
US4728323A (en) * | 1986-07-24 | 1988-03-01 | Minnesota Mining And Manufacturing Company | Antimicrobial wound dressings |
US4895566A (en) * | 1986-07-25 | 1990-01-23 | C. R. Bard, Inc. | Coating medical devices with cationic antibiotics |
US5290548A (en) * | 1987-04-10 | 1994-03-01 | University Of Florida | Surface modified ocular implants, surgical instruments, devices, prostheses, contact lenses and the like |
US4806382A (en) * | 1987-04-10 | 1989-02-21 | University Of Florida | Ocular implants and methods for their manufacture |
US5100689A (en) * | 1987-04-10 | 1992-03-31 | University Of Florida | Surface modified surgical instruments, devices, implants, contact lenses and the like |
US5108776A (en) * | 1987-04-10 | 1992-04-28 | University Of Florida | Ocular implants and methods for their manufacture |
US5080893A (en) * | 1988-05-31 | 1992-01-14 | University Of Florida | Method for preventing surgical adhesions using a dilute solution of polymer |
US5306289A (en) * | 1987-08-26 | 1994-04-26 | United States Surgical Corporation | Braided suture of improved characteristics |
GB8720502D0 (en) * | 1987-08-29 | 1987-10-07 | Giltech Ltd | Antimicrobial composition |
US5201724A (en) * | 1987-12-23 | 1993-04-13 | The Victoria University Of Manchester | Catheter |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US4994047A (en) * | 1988-05-06 | 1991-02-19 | Menlo Care, Inc. | Multi-layer cannula structure |
US5124129A (en) * | 1988-07-29 | 1992-06-23 | Mallinckrodt Medical, Inc. | Carbon dioxide indicator |
GB8820945D0 (en) * | 1988-09-07 | 1988-10-05 | Smith & Nephew | Medical articles |
US5888441A (en) * | 1988-08-24 | 1999-03-30 | Ansell Healthcare Products Inc. | Preparation of antimicrobial articles |
US5091205A (en) * | 1989-01-17 | 1992-02-25 | Union Carbide Chemicals & Plastics Technology Corporation | Hydrophilic lubricious coatings |
US4999210A (en) * | 1989-01-18 | 1991-03-12 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
US6261271B1 (en) * | 1989-01-18 | 2001-07-17 | Becton Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
IE64997B1 (en) * | 1989-01-18 | 1995-10-04 | Becton Dickinson Co | Anti-infection and antithrombogenic medical articles and method for their preparation |
US5165952A (en) * | 1989-01-18 | 1992-11-24 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
US4925668A (en) * | 1989-01-18 | 1990-05-15 | Becton, Dickinson And Company | Anti-infective and lubricious medical articles and method for their preparation |
US5013306A (en) * | 1989-01-18 | 1991-05-07 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
US5181505A (en) * | 1989-03-08 | 1993-01-26 | Lew Chel W | Method and apparatus for delivery of a medicament in the oral cavity |
US4990357A (en) * | 1989-05-04 | 1991-02-05 | Becton, Dickinson And Company | Elastomeric segmented hydrophilic polyetherurethane based lubricious coatings |
US4990158A (en) * | 1989-05-10 | 1991-02-05 | United States Surgical Corporation | Synthetic semiabsorbable tubular prosthesis |
US5061254A (en) * | 1989-06-21 | 1991-10-29 | Becton, Dickinson And Company | Thermoplastic elastomeric hydrophilic polyetherurethane expandable catheter |
JP2752465B2 (en) * | 1989-10-20 | 1998-05-18 | 三菱化学株式会社 | Manufacturing method of antibacterial polyolefin resin molded product |
US5089205A (en) * | 1989-09-25 | 1992-02-18 | Becton, Dickinson And Company | Process for producing medical devices having antimicrobial properties |
US5049132A (en) * | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5181923A (en) * | 1990-03-26 | 1993-01-26 | United States Surgical Corporation | Spiroid braided suture |
US5102983A (en) * | 1990-04-02 | 1992-04-07 | United States Surgical Corporation | Process for preparing foamed, bioabsorbable polymer particles |
US5179174A (en) * | 1990-04-23 | 1993-01-12 | C. R. Bard, Inc. | Flexible lubricious organic coatings |
WO1991017724A1 (en) * | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US5417671A (en) * | 1990-05-23 | 1995-05-23 | Jackson; Richard R. | Medical devices having local anesthetic effect and methods of their manufacture |
US5279594A (en) * | 1990-05-23 | 1994-01-18 | Jackson Richard R | Intubation devices with local anesthetic effect for medical use |
US5328698A (en) * | 1990-08-06 | 1994-07-12 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic and/or anti-infective |
US5302392A (en) * | 1990-08-20 | 1994-04-12 | Becton, Dickinson And Company | Polyurethane sponge having rapid iodine release |
US5302385A (en) * | 1990-08-20 | 1994-04-12 | Becton, Dickinson And Company | Polyurethane-polyvinylpyrrolidone block copolymer and iodine carrier therefrom |
US5102401A (en) * | 1990-08-22 | 1992-04-07 | Becton, Dickinson And Company | Expandable catheter having hydrophobic surface |
US5160790A (en) * | 1990-11-01 | 1992-11-03 | C. R. Bard, Inc. | Lubricious hydrogel coatings |
DE4105235A1 (en) * | 1991-02-20 | 1992-08-27 | Merck Patent Gmbh | COATED SYSTEM |
US5296238A (en) * | 1991-02-26 | 1994-03-22 | Toagosei Chemical Industry Co., Inc. | Microbicides |
AU1579092A (en) * | 1991-02-27 | 1992-10-06 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
US5038777A (en) * | 1991-03-14 | 1991-08-13 | Dunn Margarette T | Endotracheal device |
US5443907A (en) * | 1991-06-18 | 1995-08-22 | Scimed Life Systems, Inc. | Coating for medical insertion guides |
FR2679142B1 (en) * | 1991-07-18 | 1995-06-09 | Nice Sophia Antipolis Universi | PROCESS FOR THE PROTECTION OF PROSTHESES, IMPLANTABLE PROVISIONAL OR DEFINITIVE MATERIALS AGAINST COLONIZATION AND BACTERIAL INFECTION. |
US5282829A (en) * | 1991-08-15 | 1994-02-01 | United States Surgical Corporation | Hollow body implants |
US5275618A (en) * | 1991-11-13 | 1994-01-04 | United States Surgical Corporation | Jet entangled suture yarn and method for making same |
US5250620A (en) * | 1991-11-21 | 1993-10-05 | Miles Inc. | Hydrophilic polyvinylpyrrolidone compositions having a low coefficient of friction |
JPH05220216A (en) * | 1992-02-15 | 1993-08-31 | Kawasumi Lab Inc | In vivo insertion tube |
US5225485A (en) * | 1992-03-03 | 1993-07-06 | United States Surgical Corporation | Polyetherimide ester suture and its method of manufacture and method of use |
US5569184A (en) * | 1992-04-29 | 1996-10-29 | Cardiovascular Dynamics, Inc. | Delivery and balloon dilatation catheter and method of using |
US5492763A (en) * | 1992-06-08 | 1996-02-20 | Spire Corporation | Infection resistant medical devices and process |
DE4226810C1 (en) * | 1992-08-13 | 1994-01-27 | Theodor Dipl Ing Krall | Hoses and other objects made of plastic for medical use, which are not colonized by germs and processes for their manufacture |
US5284489A (en) * | 1992-08-19 | 1994-02-08 | United States Surgical Corporation | Filament fabricated from a blend of ionomer resin and nonionic thermoplastic resin |
PT590348E (en) * | 1992-09-26 | 2002-07-31 | Aventis Bulk S P A | CATHETERS OF CENTRAL VEINS CHARGED WITH LIPODALBA-HEPTIDEO ANTIBIOTICS TO PREVENT THE DEVELOPMENT OF CATHETER RELATED INFECTIONS |
US5599291A (en) * | 1993-01-04 | 1997-02-04 | Menlo Care, Inc. | Softening expanding ureteral stent |
US5349045A (en) * | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
US5848995A (en) * | 1993-04-09 | 1998-12-15 | Walder; Anthony J. | Anti-infective medical article and method for its preparation |
DE4316920A1 (en) * | 1993-05-20 | 1994-11-24 | Michael Dr Med Hartmann | Endotracheal tube |
US5403347A (en) * | 1993-05-27 | 1995-04-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
NZ533467A (en) * | 1993-07-19 | 2006-02-24 | Angiotech Pharm Inc | Anti-angiogenic compositions and methods of use |
US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US5395398A (en) * | 1993-07-28 | 1995-03-07 | C. R. Bard, Inc. | Microelectric apparatus for the antisepsis, promulgation of healing and analgesia of wound and chronic skin ulcers |
US6361526B1 (en) * | 1993-11-01 | 2002-03-26 | Medtronic Xomed, Inc. | Antimicrobial tympanostomy tube |
EP0735852B1 (en) * | 1993-12-20 | 1999-09-22 | Biopolymerix, Inc. | Liquid dispenser for sterile solutions |
US5554147A (en) * | 1994-02-01 | 1996-09-10 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
US5976562A (en) * | 1994-02-01 | 1999-11-02 | Krall; Theodor | Process for producing bactericidal/fungicidal plastic bodies |
US5505952A (en) * | 1994-04-19 | 1996-04-09 | United States Surgical Corporation | Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom |
US5502042A (en) * | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
US6339130B1 (en) * | 1994-07-22 | 2002-01-15 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US5480963A (en) * | 1994-07-22 | 1996-01-02 | United States Surgical Corporation | Absorbable copolymers derived from tricarboxylic acids and surgical articles made therefrom |
US6046143A (en) * | 1994-08-22 | 2000-04-04 | Becton Dickinson And Company | Water soluble lubricant for medical devices |
US5507777A (en) * | 1994-10-07 | 1996-04-16 | United States Surgical Corporation | Method and apparatus for treating a portion of a suture and forming a suture tip for attachment to a needle |
US5618313A (en) * | 1994-10-11 | 1997-04-08 | United States Surgical Corporation | Absorbable polymer and surgical articles fabricated therefrom |
JPH08117327A (en) * | 1994-10-20 | 1996-05-14 | Nippon Zeon Co Ltd | Medical instrument to be retained intravescularly |
US5480961A (en) * | 1994-11-03 | 1996-01-02 | United States Surgical Corporation | Bioabsorbable polymers derived from cyclic ether esters and surgical articles made therefrom |
US5614310A (en) * | 1994-11-04 | 1997-03-25 | Minnesota Mining And Manufacturing Company | Low trauma wound dressing with improved moisture vapor permeability |
US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US6169138B1 (en) * | 1994-12-15 | 2001-01-02 | Saint-Gobain Performance Plastics Corporation | Foamed pressure sensitive tapes |
US6017577A (en) * | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
GB9502253D0 (en) * | 1995-02-06 | 1995-03-29 | Giltech Ltd | The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro |
GB9511233D0 (en) * | 1995-06-03 | 1995-07-26 | Watson Jermey | Lubricious coatings |
US5643628A (en) * | 1995-06-05 | 1997-07-01 | United States Surgical Corporation | Suture tipping apparatus and method |
AU6251196A (en) * | 1995-06-07 | 1996-12-30 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical dev ice and method for loading and reloading the device therein |
US5731087A (en) * | 1995-06-07 | 1998-03-24 | Union Carbide Chemicals & Plastics Technology Corporation | Lubricious coatings containing polymers with vinyl and carboxylic acid moieties |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5620738A (en) * | 1995-06-07 | 1997-04-15 | Union Carbide Chemicals & Plastics Technology Corporation | Non-reactive lubicious coating process |
US5744151A (en) * | 1995-06-30 | 1998-04-28 | Capelli; Christopher C. | Silver-based pharmaceutical compositions |
FR2738813B1 (en) * | 1995-09-15 | 1997-10-17 | Saint Gobain Vitrage | SUBSTRATE WITH PHOTO-CATALYTIC COATING |
CZ297518B6 (en) * | 1995-09-15 | 2007-01-03 | Rhodia Chimie | Substrate provided with coating exhibiting photocatalytic properties, glazing material containing such substrate, use of said substrate, process for producing thereof, dispersion for the production process as well as use of such dispersion in the pro |
US5894042A (en) * | 1996-02-26 | 1999-04-13 | Technology Licensing Company | Bacteriostatic coating of polymeric conduit |
US5709691A (en) * | 1996-03-11 | 1998-01-20 | Morejon; Orlando | Endotracheal tube cleaning device |
US6494208B1 (en) * | 1996-03-11 | 2002-12-17 | Orlando Morejon | Endotracheal tube cleaning apparatus |
US20040081706A1 (en) * | 1996-03-13 | 2004-04-29 | Eilidh Trainer | Alginate containing antimicrobial composition |
US5727553A (en) * | 1996-03-25 | 1998-03-17 | Saad; Saad A. | Catheter with integral electromagnetic location identification device |
US6461644B1 (en) * | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
GB9607201D0 (en) * | 1996-04-04 | 1996-06-12 | Boc Group Plc | Medical article |
US6033719A (en) * | 1996-04-25 | 2000-03-07 | Medtronic, Inc. | Method for covalent attachment of biomolecules to surfaces of medical devices |
US5891506A (en) * | 1996-08-09 | 1999-04-06 | Medtronic, Inc. | Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices |
US5728420A (en) * | 1996-08-09 | 1998-03-17 | Medtronic, Inc. | Oxidative method for attachment of glycoproteins to surfaces of medical devices |
US5945319A (en) * | 1996-04-25 | 1999-08-31 | Medtronic, Inc. | Periodate oxidative method for attachment of biomolecules to medical device surfaces |
US5925552A (en) * | 1996-04-25 | 1999-07-20 | Medtronic, Inc. | Method for attachment of biomolecules to medical devices surfaces |
US6628987B1 (en) * | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
CA2206674A1 (en) * | 1996-05-30 | 1997-11-30 | Gregor Reid | Lactobacillus therapies |
US5811151A (en) * | 1996-05-31 | 1998-09-22 | Medtronic, Inc. | Method of modifying the surface of a medical device |
US5891167A (en) * | 1996-06-19 | 1999-04-06 | United States Surgical Corporation | Collagen coated gut suture |
JP3541627B2 (en) * | 1996-07-16 | 2004-07-14 | 東レ株式会社 | Graft polymer and molded article for medical use using the same |
US5993972A (en) * | 1996-08-26 | 1999-11-30 | Tyndale Plains-Hunter, Ltd. | Hydrophilic and hydrophobic polyether polyurethanes and uses therefor |
US6017334A (en) * | 1996-10-03 | 2000-01-25 | Board Of Regents, The University Of Texas System | Modified surfaces resistant to bacterial colonization |
US6191236B1 (en) * | 1996-10-11 | 2001-02-20 | United States Surgical Corporation | Bioabsorbable suture and method of its manufacture |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6685943B1 (en) * | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
JPH10323386A (en) * | 1997-03-21 | 1998-12-08 | Nippon Sherwood Medical Ind Ltd | Antibacterial catheter against blood coagulation |
KR100246927B1 (en) * | 1997-06-10 | 2000-03-15 | 손욱 | Composition of single-layer typed light conductive layer using charge transfering adhesive body system and manufacturing method thereof |
US5928174A (en) * | 1997-11-14 | 1999-07-27 | Acrymed | Wound dressing device |
US6680195B1 (en) * | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
US6526977B1 (en) * | 1998-03-09 | 2003-03-04 | Goebel Fred G. | Tracheal breathing apparatus |
US6176894B1 (en) * | 1998-06-17 | 2001-01-23 | Praxair Technology, Inc. | Supersonic coherent gas jet for providing gas into a liquid |
AU5153399A (en) * | 1998-08-14 | 2000-03-06 | Coloplast A/S | Stabilised compositions having antibacterial activity |
US6273875B1 (en) * | 1998-08-17 | 2001-08-14 | Edwards Lifesciences Corporation | Medical devices having improved antimicrobial/antithrombogenic properties |
US6436422B1 (en) * | 1998-11-23 | 2002-08-20 | Agion Technologies L.L.C. | Antibiotic hydrophilic polymer coating |
WO2000051566A1 (en) * | 1999-03-04 | 2000-09-08 | United States Surgical Corporation | Scar reduction |
US20010041870A1 (en) * | 1999-03-09 | 2001-11-15 | Edward M. Gillis | Implantable device for access to a treatment site |
AU3771000A (en) * | 1999-03-25 | 2000-10-09 | United States Surgical Corporation | Method of promoting angiogenesis |
US6168580B1 (en) * | 1999-03-26 | 2001-01-02 | Iontophoretics Corporation | Antimicrobial device and methods for long-term catheters |
JP4014334B2 (en) * | 1999-04-23 | 2007-11-28 | 株式会社Adeka | Antibacterial deodorant cosmetic |
PT1196150E (en) * | 1999-06-14 | 2005-11-30 | Imp College Innovations Ltd | BIOACTIVE GLASS COMPOSITIONS DERIVED FROM SOL-GEL CONTAINING SILVER |
JP3971059B2 (en) * | 1999-07-15 | 2007-09-05 | 東亞合成株式会社 | Glass antibacterial agent |
US6475631B1 (en) * | 1999-07-15 | 2002-11-05 | Toagosei Co., Ltd. | Antimicrobial agent, antimicrobial resin composition and antimicrobial artificial marble |
WO2001006973A1 (en) * | 1999-07-28 | 2001-02-01 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
US20040038327A1 (en) * | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
GB9924694D0 (en) * | 1999-10-20 | 1999-12-22 | Giltech Ltd | Anti-microbial device |
US6471672B1 (en) * | 1999-11-10 | 2002-10-29 | Scimed Life Systems | Selective high pressure dilation balloon |
US20060013850A1 (en) * | 1999-12-03 | 2006-01-19 | Domb Abraham J | Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom |
US6677431B2 (en) * | 1999-12-10 | 2004-01-13 | The Trustees Of The University Of Pennsylvania | Design, preparation, and properties of antibacterial β-peptides |
US6716895B1 (en) * | 1999-12-15 | 2004-04-06 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
US6517838B1 (en) * | 2000-06-16 | 2003-02-11 | The Texas A&M University System | Decorin binding protein essential peptides and methods of use |
US6989189B2 (en) * | 2000-06-30 | 2006-01-24 | Mondi Inncoat Gmbh | Separable layer of bonding material, laminate and method for making same |
US6443156B1 (en) * | 2000-08-02 | 2002-09-03 | Laura E. Niklason | Separable double lumen endotracheal tube |
US6450164B1 (en) * | 2000-08-17 | 2002-09-17 | Michael J. Banner | Endotracheal tube pressure monitoring system and method of controlling same |
GB0023131D0 (en) * | 2000-09-21 | 2000-11-01 | Hunter Gary F | Catheters |
US6855422B2 (en) * | 2000-09-21 | 2005-02-15 | Monte C. Magill | Multi-component fibers having enhanced reversible thermal properties and methods of manufacturing thereof |
US6487446B1 (en) * | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
US6797743B2 (en) * | 2000-09-27 | 2004-09-28 | Michigan Biotechnology Institute | Antimicrobial polymer |
NZ526821A (en) * | 2001-01-18 | 2005-02-25 | Genzyme Corp | Ionene polymers and their use as antimicrobial agents |
FR2821140B1 (en) * | 2001-02-16 | 2003-05-23 | Syegon | PILOTED PNEUMATIC VALVE |
US7393547B2 (en) * | 2001-04-11 | 2008-07-01 | Helix Medical, Llc | Antimicrobial elastomer composition and method for making |
EP1443957A4 (en) * | 2001-05-08 | 2005-10-12 | Texas A & M Univ Sys | Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them |
US6716207B2 (en) * | 2001-05-22 | 2004-04-06 | Scimed Life Systems, Inc. | Torqueable and deflectable medical device shaft |
US6576329B2 (en) * | 2001-06-12 | 2003-06-10 | Exxonmobil Oil Corporation | Multilayer thermoplastic film |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
JP5041636B2 (en) * | 2001-07-12 | 2012-10-03 | 株式会社Adeka | Antimicrobial composition for medical devices |
US6629969B2 (en) * | 2001-07-26 | 2003-10-07 | Durect Corporation | Catheter for modification of agent formulation |
AU2002367825A1 (en) * | 2001-07-30 | 2003-10-13 | Sts Biopolymers, Inc. | Graft polymer matrices |
US20030100829A1 (en) * | 2001-11-27 | 2003-05-29 | Sheng-Ping Zhong | Medical devices with magnetic resonance visibility enhancing material |
JP2005536185A (en) * | 2002-03-05 | 2005-12-02 | インヒビテックス インコーポレーテッド | Monoclonal and polyclonal antibodies that recognize coagulase-negative staphylococcal proteins |
US20040022775A1 (en) * | 2002-04-15 | 2004-02-05 | Gregor Reid | Methods of treating viral infections in mammals |
FR2838734B1 (en) * | 2002-04-17 | 2005-04-15 | Saint Gobain | SELF-CLEANING COATING SUBSTRATE |
US7393501B2 (en) * | 2002-05-29 | 2008-07-01 | Nano Vibronix Inc | Method, apparatus and system for treating biofilms associated with catheters |
WO2004013167A2 (en) * | 2002-08-01 | 2004-02-12 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from enterococcus faecalis |
US7238669B2 (en) * | 2002-09-11 | 2007-07-03 | The Curators Of The University Of Missouri | Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
US6770729B2 (en) * | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
AU2003291087A1 (en) * | 2002-11-19 | 2004-06-15 | Genzyme Corporation | Ionene oligomers and polymers |
AU2003295636A1 (en) * | 2002-11-19 | 2004-06-15 | Genzyme Corporation | Polyionene polymers with hydrolyzable linkages |
BRPI0407142A (en) * | 2003-02-14 | 2006-01-10 | Depuy Spine Inc | In situ intervertebral fusion device |
JP4293806B2 (en) * | 2003-02-28 | 2009-07-08 | 石塚硝子株式会社 | Antibacterial imparting glass composition and antibacterial polymer composite material using the same |
US20040220534A1 (en) * | 2003-04-29 | 2004-11-04 | Martens Paul W. | Medical device with antimicrobial layer |
HUE045608T2 (en) * | 2003-06-06 | 2020-01-28 | Univ Texas | Antimicrobial flush solutions |
US7588033B2 (en) * | 2003-06-18 | 2009-09-15 | Breathe Technologies, Inc. | Methods, systems and devices for improving ventilation in a lung area |
US20050064020A1 (en) * | 2003-08-14 | 2005-03-24 | Schuette Robert L. | Method for producing silver-containing antimicrobial fabric |
EP1691614B1 (en) * | 2003-12-04 | 2013-02-13 | University Of Iowa Research Foundation | Gallium inhibits biofilm formation |
US20060014285A1 (en) * | 2004-07-14 | 2006-01-19 | Eldridge Gary R | Methods and compositions for inhibiting biofilms |
US7713539B2 (en) * | 2004-07-19 | 2010-05-11 | Boston Scientific Scimed, Inc. | Medical devices containing radiation resistant block copolymer |
DE102005042372B3 (en) * | 2005-09-07 | 2007-01-18 | Dräger Medical AG & Co. KG | Artificial respiration and/or anesthetic device comprises hydrophilic polymer material surface that contains silver particle and mineral filler such as zeolite, silicon dioxide, titanium dioxide, alumina, and zircon oxide |
-
2003
- 2003-04-29 US US10/425,030 patent/US20040220534A1/en not_active Abandoned
-
2004
- 2004-04-29 CA CA002523857A patent/CA2523857A1/en not_active Abandoned
- 2004-04-29 WO PCT/US2004/013196 patent/WO2004096330A2/en active Application Filing
- 2004-04-29 AU AU2004234001A patent/AU2004234001B2/en not_active Ceased
- 2004-04-29 DE DE602004027899T patent/DE602004027899D1/en not_active Expired - Lifetime
- 2004-04-29 JP JP2006513421A patent/JP2006525089A/en active Pending
- 2004-04-29 EP EP04760444A patent/EP1617890B1/en not_active Expired - Lifetime
- 2004-04-29 AT AT04760444T patent/ATE472343T1/en not_active IP Right Cessation
-
2006
- 2006-01-24 US US11/337,996 patent/US20060118122A1/en not_active Abandoned
- 2006-01-24 US US11/337,995 patent/US20060118121A1/en not_active Abandoned
-
2010
- 2010-12-01 US US12/958,091 patent/US20110067703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004234001A1 (en) | 2004-11-11 |
WO2004096330A2 (en) | 2004-11-11 |
EP1617890A2 (en) | 2006-01-25 |
US20060118122A1 (en) | 2006-06-08 |
US20060118121A1 (en) | 2006-06-08 |
DE602004027899D1 (en) | 2010-08-12 |
JP2006525089A (en) | 2006-11-09 |
CA2523857A1 (en) | 2004-11-11 |
ATE472343T1 (en) | 2010-07-15 |
AU2004234001B2 (en) | 2010-08-12 |
US20040220534A1 (en) | 2004-11-04 |
US20110067703A1 (en) | 2011-03-24 |
WO2004096330A3 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1617890B1 (en) | Medical device with antimicrobial layer | |
JP2006525089A5 (en) | ||
AU666573B2 (en) | Suction catheter assemblies | |
US20120132212A1 (en) | Endotracheal Tube with Multi-Mode Valve and Method of Using Same | |
US5638812A (en) | Coated medico-surgical devices | |
CN101579550B (en) | Artificial trachea cannula made of nano materials and preparation method thereof | |
CA1175727A (en) | Multi-purpose tracheal tube | |
US8042544B2 (en) | Prevention of ventilator associated pneumonia (VAP) | |
CN102905749B (en) | There is the endotracheal intubation of one or more blockage element, blockage element and the method using blockage element | |
US20090255536A1 (en) | Biofilm-Inhibiting Catheters and Tubings | |
US8408210B2 (en) | Cuffless tracheal tube | |
US20090320834A1 (en) | Dilator Loading Catheter | |
US20080078406A1 (en) | Endotracheal tube and technique for using the same | |
US20090101152A1 (en) | High surface area anti-microbial coated endotracheal tube | |
CN113350579B (en) | Preparation method of anti-sputum-thrombus tracheal catheter loaded with hydrogel coating | |
CN102389616A (en) | Antibacterial medical catheter coated with nano silver polymer cellular structure film | |
CN101554505A (en) | Artificial trachea cannula with nanometre anti-microbial coating | |
US20100051035A1 (en) | Low-pressure airway management device with active coating and method for patient care | |
CN201949389U (en) | Antibacterial medical catheter with nano silver/polymer honeycomb films | |
US20230181852A1 (en) | Endotracheal device for mechanical ventilation of a patient | |
CN201404565Y (en) | Artificial trachea cannula with nano antibiotic material coating | |
CN201481948U (en) | Artificial trachea cutting sleeve of anti-bacterial nano material coating layer | |
CN213252265U (en) | Tracheal catheter with inner sleeve | |
Wang et al. | Reduction of biofilm formation in rabbits by novel nano-silver/polyurethane coated endotracheal tube | |
Yarham et al. | Ventilator-associated pneumonia and new airway technologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051122 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070427 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: POTTER, ADIN M. Inventor name: MARTENS, PAUL, W. Inventor name: NIETO, ROBERT, L. Inventor name: VIRAG, ROBERT |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602004027899 Country of ref document: DE Date of ref document: 20100812 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101001 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101102 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20110331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101011 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004027899 Country of ref document: DE Effective date: 20110330 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20111101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110430 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111101 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110430 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20120209 AND 20120215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602004027899 Country of ref document: DE Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602004027899 Country of ref document: DE Owner name: TYCO HEALTHCARE GROUP LP, US Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, US Effective date: 20121002 Ref country code: DE Ref legal event code: R082 Ref document number: 602004027899 Country of ref document: DE Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU Effective date: 20121002 Ref country code: DE Ref legal event code: R081 Ref document number: 602004027899 Country of ref document: DE Owner name: TYCO HEALTHCARE GROUP LP, MANSFIELD, US Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, MO., US Effective date: 20121002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110429 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20130425 Year of fee payment: 10 Ref country code: DE Payment date: 20130429 Year of fee payment: 10 Ref country code: GB Payment date: 20130429 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130506 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100630 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004027899 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140429 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004027899 Country of ref document: DE Effective date: 20141101 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141101 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140429 |